Abstracts Archive - Page 1640 of 2425 - ACR Meeting Abstracts

Abstract Number: 2519 • 2015 ACR/ARHP Annual Meeting
Pregnancy in Psoriatic Arthritis: A Case Series
Maria Mouyis¹, Clare Thornton¹, David Williams^2,3 and Ian Giles⁴, ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Institute for Women’s Health, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: It is recognised that active disease in women with inflammatory arthritis is associated with adverse pregnancy outcomes. Most studies however, have focussed upon patients…
Abstract Number: 2520 • 2015 ACR/ARHP Annual Meeting
Psoriatic Arthritis Activity during Pregnancy and the Postpartum� Period
Ari Polachek¹, Suzanne Li², Vinod Chandran¹ and Dafna Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd -4thdecades of life, including women of childbearing age. However, little is known about PsA activity during…
Abstract Number: 2521 • 2015 ACR/ARHP Annual Meeting
Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes
Anja Strangfeld¹, Dagmar Pattloch¹, Madlen Spilka², Bernhard Manger³, Brigitte Krummel-Lorenz⁴, Annett Gräßler⁵, Joachim Listing⁶ and Angela Zink^1,7, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, Erlangen, Germany, ⁴Rheumatologist, Frankfurt, Germany, ⁵Rheumatologist, Pirna, Germany, ⁶Epidemiologiy, German Rheumatism Research Center, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany
Background/Purpose: The assumption of spontaneous remission among pregnant women with rheumatoid arthritis (RA) is common. Nevertheless, prospectively collected data describing the course of disease activity…
Abstract Number: 2522 • 2015 ACR/ARHP Annual Meeting
High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception
Rebecca Fischer-Betz¹, Oliver Sander¹, Christof Specker², Ralph Brinks³ and Matthias Schneider¹, ¹Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Rheumatology and clinical immunology, Kliniken Essen Sued, Essen, Germany, ³Hiller Center for Research in Rheumatology, Duesseldorf, Germany
Background/Purpose: Optimal treatment of women with Rheumatoid Arthritis (RA) during pregnancy remains a challenge, mainly due to safety concerns. TNF inhibitors (TNFi) are now routinely…
Abstract Number: 2523 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Megan E. B. Clowse¹, Douglas C. Wolf², Amanda Golembesky³, Laura Shaughnessy⁴, Dirk De Cuyper⁵ and Frauke Förger⁶, ¹Rheumatology & Immunology, Duke University, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³UCB Pharma, Raleigh, NC, ⁴8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁵Safety Patient Solutions BioBrands, UCB Pharma, Brussels, Belgium, ⁶Rheumatology, Clinical Immunology and Allergology, Inselspital-University Hospital, Bern, Switzerland
Background/Purpose: Data on the impact of anti-TNF medications on pregnancy outcomes are limited. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in more than…
Abstract Number: 2524 • 2015 ACR/ARHP Annual Meeting
Longterm Follow-up of Children Born to Mothers with Chronic Arthritides and Exposed to Anti-TNF Alfa Agents during Pregancy and Breastfeeding: A Case-Control Study
Rossella Reggia¹, Laura Andreoli¹, Chiara Bazzani¹, Maria Grazia Lazzaroni¹, Giovanna Mazza¹, Michele Agosti¹, Roberto Gorla², Marco Taglietti², Andrea Lojacono³, Mario Motta⁴ and Angela Tincani⁵, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Neonatal Intensive Care Unit, University and Spedali Civili of Brescia, Brescia, Italy, ⁵Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Anti-TNFalfa agents have been used to control disease activity of patients with Chronic Arthritides (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis) during the wash-out period…
Abstract Number: 2525 • 2015 ACR/ARHP Annual Meeting
Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions
Rishi J. Desai¹, Krista Huybrechts², Brian Bateman², Sonia Hernandez-diaz³, Helen Mogun², Chandrasekar Gopalakrishnan⁴, Elisabetta Patorno⁴ and Seoyoung C. Kim⁵, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic inflammatory conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) affect many women during their…
Abstract Number: 2526 • 2015 ACR/ARHP Annual Meeting
Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-Based Study
Mary A De Vera^1,2, Eric C. Sayre², Nicole Tsao^1,2 and J Antonio Avina-Zubieta^2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-based StudyBackground/Purpose: Although the incidence of RA peaks during the 4th and 5th decades…
Abstract Number: 2527 • 2015 ACR/ARHP Annual Meeting
Neonatal Outcome to Paternal Exposures with Anti-Rheumatic Therapy
Elisabeth Solau-Gervais¹ and Antoine Brigaud Jr.², ¹Rhumatologie, University Hospital, Poitiers, France, ²University hospital, Poitiers, France
Background/Purpose: There is a lack of studies about preconceptional paternal exposure to disease modified anti-rheumatic drugs (DMARDs) and the data of literature are controversial. The…
Abstract Number: 2528 • 2015 ACR/ARHP Annual Meeting
Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases
Jie Zhang^1,2, Jeffrey R. Curtis³, Fenglong Xie⁴, Melissa L. Mannion⁵, James D. Lewis^6,7, Megan E. B. Clowse⁸, Kenneth G. Saag³, Steven Bethard⁹, Jospeh Biggio⁹, Gerald McGwin⁹ and Timothy Beukelman¹⁰, ¹Epidemilogy, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Medicine, University of Pennsylvania, Philadelphia, PA, ⁸Clinical Rheumatologist, Duke University Medical Center, Durham, NC, ⁹UAB, Birmingham, AL, ¹⁰Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To examine difference in the prevalence of immunosuppressive medication use during pregnancy by type of autoimmune disease and by insurance (Medicaid versus commercial) in…
Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Gail Deutsch^1,2, Megan Yuasa³ and Anne M. Stevens^4,5, ¹Pathology, Seattle Children's Hospital, Seattle, WA, ²School of Medicine, University of Washington, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁵Pediatrics, University of Washington, Seattle, WA
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
Abstract Number: 2530 • 2015 ACR/ARHP Annual Meeting
A Multicenter Evaluation of Obstetric and Maternal Outcome in Prospectively Followed Pregnant Patients with Confirmed Positivity for Antiphospholipid Antibodies (aPL)
Micaela Fredi¹, Elena Aggogeri², Elisa Bettiga³, Laura Andreoli², Maria Grazia Lazzaroni², Véronique Le Guern⁴, Andrea Lojacono³, Fabrizio Lupoli², Nathalie Morel⁴, Jean Charles Piette⁵, Sonia Zatti³, Nathalie Costedoat-Chalumeau⁴ and Angela Tincani², ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France
Background/Purpose: Antiphospholipd antibodies (aPL) positivity is considered as a risk factors for a poor obstetric outcome. The aim of this work was to determine risk…
Abstract Number: 2531 • 2015 ACR/ARHP Annual Meeting
Hematologic Disorder during Pregnancy Associated with Adverse Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus
Sara K. Tedeschi¹, Hongshu Guan², Alexander Fine², Bing Lu¹, Karen H. Costenbader¹ and Bonnie Bermas¹, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies have found a relationship between overall systemic lupus erythematosus (SLE) activity and adverse pregnancy outcomes. We sought to investigate whether specific types…
Abstract Number: 2532 • 2015 ACR/ARHP Annual Meeting
Disease Activity in Women with Systemic Lupus Erythematosus during Pregnancy and the First Year Post Partum
Carina Gotestam Skorpen^1,2, Johan Skomsvoll³, Inge-Margrethe Gilboe⁴, Stian Lydersen⁵ and Marianne Wallenius³, ¹Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ²Dept of Rheumatology, Trondheim University Hospital, Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, ³Dept of Rheumatology, Trondheim University Hospital, National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, ⁴Revmatologisk avdeling seksjon, Oslo universitetssykehus HF, Rikshospitalet, Oslo, Norway, ⁵Regional Center for the health of children and adolescents, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
Disease Activity in women with SLE during pregnancy and the first year post partumBackground/Purpose: Disease activity measured by validated methods has been sparsely examined during…
Abstract Number: 2533 • 2015 ACR/ARHP Annual Meeting
A Comparison of Pregnancy Outcomes before and after Lupus Diagnosis
Megan E. B. Clowse¹, Maria Dall'Era², Jennifer M. Grossman^3,4, Diane L. Kamen⁵, Jerry McGwin⁶, Robert Roubey⁷ and Jill P. Buyon⁸, ¹Rheumatology & Immunology, Duke University, Durham, NC, ²University of California San Francisco School of Medicine, San Francisco, CA, ³Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁴Rheumatology, UCLA, Los Angeles, CA, ⁵Medicine, Medical University of South Carolina, Charleston, SC, ⁶Deparment of Epidemiology, University Of Alabama at Birmingham, School of Public Health, Birmingham, AL, ⁷University of North Carolina, Chapel Hill, NC, ⁸Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The frequency of pregnancy complications, including miscarriage, stillbirth, preeclampsia, and preterm birth varies between lupus cohorts. This analysis compares pregnancy outcomes that occurred before…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].